MassBio’s President & CEO, Bob Coughlin, will host a regular virtual Town Hall for members. This will be an opportunity for our members to ask questions, hear what MassBio is up to, and learn more about the state of the industry amidst the COVID-19 pandemic.
This Town Hall will feature Matthew Harrison, a Managing Director and Head of Biotech Industry Research at Morgan Stanley, who will share predictions for the biotech outlook in 2021.
Webinar link will be emailed to participants the day before - you can also access it from the "Live Stream" tab below.
MassBio makes every effort to accommodate our entire community at each of our events. Please let us know at least 3 days in advance of the event if you require special accommodations, such as captioning.
As President and CEO of the Massachusetts Biotechnology Council, Bob’s mission is to advance Massachusetts' leadership in the life sciences to grow the industry, add value to the healthcare system and improve patient lives. Over the last decade, Bob has truly become a champion for patients by ensuring innovative companies have the best environment possible to research, develop, and commercialize breakthrough therapies and cures for people around the world who need and deserve them.
Bob has spent his career in both the public and private sectors. Before joining MassBio, he served as the Undersecretary of Economic Development within Governor Deval Patrick's administration, where he prioritized both healthcare and economic development issues and was a strong advocate for the life sciences industry in Massachusetts. Prior to that, he was elected as State Representative to the 11th Norfolk district for three terms. Bob has also held senior executive positions in the environmental services, capital management and venture capital industries. He brings passion and energy to all of his endeavors.
Managing Director, Head of Biotech Industry Research, Morgan Stanley
Matthew Harrison, a Managing Director in Research, covers the biotech industry, focusing on companies with market capitalizations of $10 billion and up. He has also covered pharmaceutical stocks, and has been highly ranked among biotech analysts on Institutional Investor’s All-American Research Poll.
Matthew received his Bachelor’s in Physics from Yale University and a Master’s in Physics, as well as a Master’s in Financial Management, from Case Western Reserve University.